SUNPHARMA

Fundamental View- Sun Pharmaceutical Industries Ltd., India’s largest pharmaceutical company and the fourth-largest global specialty generics player, continues to maintain a strong financial and operational position. With a diversified presence across over 100 countries, Sun Pharma reported consolidated revenue of ₹49,505 crore for FY24, marking a 12% YoY growth, driven by robust performance in both specialty and generics segments. The company posted a healthy net profit of ₹9,602 crore and maintained stable EBITDA margins of around 27%, supported by its high-margin specialty portfolio and strong operational efficiency. Sun Pharma remains a market leader in India’s branded generics space while expanding its global footprint, particularly in the US and emerging markets. With consistent free cash flow generation, low debt, and continued R&D investment of 6-7% of revenue, the company is well-positioned for long-term growth. Technical View- As seen on the daily chart, after making a low of ₹1636.10 on June 19, the stock has been undergoing a correction phase, yet it continues to hold the crucial ₹1600.00 support level despite negative news flow. On June 30, the stock touched a high of ₹1704.30 but faced a pullback; however, it has managed to sustain above its 14-day EMA. Today, the stock opened at ₹1656.00, made the same as its intraday low, and is currently trading positively around ₹1680.00. If this rally continues, the stock is likely to retest the ₹1700.00 level in the short term. Sustaining above ₹1700.00 would indicate strength, with the potential to find support at its 55-day EMA and gradually move towards ₹1750–1760 levels. From a technical perspective, a buy-on-dip approach can be considered with a strict stop-loss at ₹1600.00, aiming for upside levels of ₹1750–1760 in the coming sessions. Warning- ***** *****